VPN Plus+ ExclusiveIntroduction to Oncology: Easy Peasy BasicsMay 12, 2023This session: Lindsay Hallman, VTS, touches on the history of cancer, and chemotherapy, as well as the modern use of chemotherapy in veterinary medicine. The second half of the lecture focuses on common oncological emergencies, hemangiosarcoma, osteosarcoma, mast cell tumors, and lymphoma.
SPONSORED CONTENTAre Your Patients Fully Protected?Fleas, ticks, heartworms, and intestinal parasites—dogs face multiple threats. See how a multi-parasite approach can offer your patients a broad range of protection. + Learn More
Old challenges and new opportunities in treating feline lymphomaFebruary 8, 2022Lymphoma is the most common malignancy in cats and can cause a variety of clinical signs, depending on the site affected and extent of disease.
Canine lymphoma tablets OKed by FDAJanuary 13, 2022Dogs diagnosed with lymphoma can now benefit from newly approved treatment.
Canine lymphoma drug gets full approvalJuly 20, 2021Elanco’s Tanovea product contains the active ingredient rabacfosadine, an acyclic nucleotide phosphonate that kills rapidly growing tumor cells.
Is chemotherapy a viable treatment for lymphoma in horses?June 25, 2019 Lymphoma, which is cancer of the lymphatic system, is a rare medical condition of horses. However, it also is the most common malignant neoplastic condition of the horse system. Horses of any age can be affected, although it more commonly appears earlier in life (from four to 10 years of age). Lymphoma has several manifestations: multicentric, in the gastrointestinal tract, in the skin, and even in discrete settings. This disease can be difficult to recognize initially, and is typically diagnosed after it has progressed, with clinical signs relative to the affected organ or tissue. Routine hematological analysis is often not helpful, as complete blood counts and serum chemistry tests are usually normal. When hematological abnormalities do occur, they typically show as anemia, increased serum protein, and/or fibrinogen. Conversely, low serum protein levels may be seen, as well. A definitive diagnosis is made by identifying neoplastic lymphocytes, usually obtained by analysis of body fluid effusions (e.g. pleural or abdominal fluid, or by fine needle aspiration of affected tissue[s]). Depending on the form of lymphoma and how late in the disease process the horse is presented, the prognosis is usually poor. There are several treatment options, including surgical removal of isolated, …
TGen, Ethos develop diagnosis test for canine lymphomaMay 24, 2019A new test may assist veterinarians in more accurately diagnosing canine lymphoma. Developed by Ethos Veterinary Health, Ethos Discovery, and the Translational Genomics Research Institute (TGen), the test is based on the results of a study that analyzed 180 dogs with cancer. The teams used their test, ePARR, to confirm first whether the dogs in the study had lymphoma and then determined what type they had. Results indicate the test was more than 90 percent accurate among a range of lymphoma sample types. "An ongoing need exists for robust validation of molecular diagnostics in veterinary medicine. This study is an example of exhaustive validation of one such molecular test," says Will Hendricks, PhD, assistant professor in TGen's Integrated Cancer Genomics Division and one of the study's senior coauthors. "Overall, ePARR is more than 90 percent accurate across sample types and diagnostic settings." The researchers say not only could molecular-level investigations into dog DNA improve the health of dogs with cancer, but it could help understand cancer in humans, too.
The race to develop immunotherapies for canine lymphoma and osteosarcomaJanuary 2, 2019There are many reasons why development of immunotherapies in dogs has been slow. Although cancer, and in particular lymphoma and osteosarcoma, is frequent in dogs, just one percent of owners have pet insurance; those who don’t are willing to spend only a limited amount of money to treat their dog, especially when initial treatment results are not as dramatic as in humans.
Tufts veterinarians treat canine cancer with experimental drugJanuary 18, 2018When Edward Sloan's dog, Dozer, a 7-year-old bull mastiff went blind seemingly overnight, a devastating diagnosis revealed Dozer had cancer. Desperate to save his best friend, Sloan found a clinical trial at the Cummings School of Veterinary Medicine at Tufts University, where Abbey Sadowski, DVM, found that Dozer had "lost a lot of weight [and] had several weeks of history before he even saw us." Dr. Sadowski and Cheryl London, DVM, Ph.D., are testing an experimental drug—called KPT-9274—combined with just one round of chemotherapy to treat lymphoma. "We had this remarkable response … when you combine these two things together you can get a dramatic reduction in disease," Dr. London said. Early results of the small study have been promising, especially for Sloan and Dozer. "A single heroic dose … the next day he was able to see," Sloan said. Dozer is three months in remission, and his medical reversal of fortune could eventually lead to a breakthrough in human medicine. London said the outcome of a canine trial is a valuable piece of the research puzzle. "The benefits to the human side are that you get a drug into humans that's actually much …
Cornell, Tufts scientists receive $2.5M from NIH for cancer studyNovember 14, 2017Cornell and Tufts University scientists have received a five-year, $2.5 million grant from the National Institutes of Health to use dogs as a model for studying cancer immunotherapies. The dogs used in the study are treated with similar care as human patients, with the potential of being cured of lymphoma. Kristy Richards, Ph.D., MD, associate professor of Biomedical Sciences at the College of Veterinary Medicine with a joint appointment at the Division of Hematology/Medical Oncology at Weill Cornell Medicine is co-principal investigator on the grant, along with Cheryl London, DVM, Ph.D., DACVIM, a research professor at Tufts University's Cummings School of Veterinary Medicine. The grant will investigate whether combinations of PD1 inhibitors and other targeted therapies may increase effectiveness of cancer treatment in dogs, thereby setting up the possibility for human trials. Clinical trials in dogs should begin in the next six months, at which time, the researchers will reach out to referring veterinarians for candidate canine patients with lymphoma. Veterinary oncologists at the Cornell College of Veterinary Medicine and at Cornell University Veterinary Specialists in Stamford, Conn., will enroll and treat patients during the trials. Patients also will be enrolled at the …
Orofacial manifestations of lymphoma in petsJuly 27, 2017The disease covered in this month’s column qualifies as rare. Each year, I see perhaps only two or three cases. However, it’s important to understand, as it can mimic other less serious diseases, often delaying diagnosis. One retrospective study noted that median time between onset and diagnosis was five months.
